Mirum Pharmaceuticals Inc (MIRM)
Mirum Pharma - Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome
Mirum Pharma - Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak clinical signals • Minimal impact anticipated **Sentiment:** Neutral (50%) **Content type:** Clinical